Nav: Home

PCSK9 inhibitior bococizumab produces varying results

March 17, 2017

Bococizumab significantly reduces cardiovascular events in high-risk patients with high LDL cholesterol levels. Development of the drug was stopped after some patients experienced a reduction in cholesterol lowering over time.

New results from the clinical trial program, SPIRE (Studies of PCSK9 Inhibition and the Reduction of Vascular Events), which sought to determine the effect of bococizumab, a PCSK9 inhibitor, on LDL cholesterol levels and clinical outcomes in high-risk patients already taking statin therapy, were presented at the 2017 American College of Cardiology Scientific Sessions and simultaneously published in two manuscripts in the New England Journal of Medicine.

Researchers report that bococizumab had short-term benefits on lowering cholesterol levels and significantly reduced the risk of cardiovascular events by 21 percent compared to placebo among those who had baseline LDL cholesterol levels of greater than 100 mg/dL. However, the cholesterol lowering effect tended to diminish over time in some patients and bococizumab did not reduce cardiovascular event rates among those with LDL levels lower than 100 mg/dL.

"Our PCSK9 inhibitor data support the notion that lowering cholesterol beyond what is possible with diet, exercise and statin therapy confers benefits to our high risk patients with cardiovascular disease, " said Paul M Ridker, MD, a senior physician at Brigham and Women's Hospital and the Eugene Braunwald Professor of Medicine at Harvard Medical School. "The new data show a meaningful reduction in cardiovascular events in the highest-risk patients who had the highest LDL cholesterol levels, despite already taking high-intensity statin therapy."

The SPIRE program involved eight double-blind, placebo controlled clinical trials that were conducted simultaneously. Six lipid-lowering trials randomized 4,449 patients, who previously had a heart attack or stroke or had extremely high baseline cholesterol levels and were on statin therapy, to receive either bococizumab (150 mg subcutaneously every 2 weeks) or placebo to determine the effects on LDL levels. Two other multi-national trials randomized 27,438 patients to either bococizumab or placebo and were designed to evaluate the impact of the drug on cardiovascular outcomes, including nonfatal heart attack and stroke, hospitalization for unstable angina requiring urgent revascularization, or cardiovascular death. Almost all the patients were on statin therapy.

On November 1, 2016, the entire SPIRE clinical trials program was stopped when the sponsor, Pfizer, who manufactures bococizumab, discontinued the development of the drug when initial results from the LDL cholesterol lowering trials indicated that some trial participants had developed anti-drug antibodies, an immunologic response to the drug. Further analysis indicated that bococizumab effectively reduced LDL cholesterol levels by an average of 56 percent after 14 weeks; however, the immunologic reaction attenuated the reduction in LDL cholesterol in approximately 15 percent of those who received the drug. Data also show that there was a wide variation in the magnitude of cholesterol reduction that patients achieved with bococizumab, even among patients who did not develop the immunologic response.

Bococizumab is a humanized antibody therapy that works by blocking proprotein convertase subtilisin-kexin 9 (PCSK), a protein that reduces the liver's ability to remove LDL cholesterol from the blood. "We believe that the attenuation of LDL lowering over time in the treatment group was likely due to the fact that bococizumab, a humanized antibody, led to an immunologic response in some patients. The alternative PCSK9 inhibitors evolocumab and alirocumab, which have already been approved for use, are fully human antibodies and do not have this adverse effect."

Researchers report that the only substantial difference in safety outcomes between the placebo and bococizumab groups was injection site reactions, which is also the result of the immunologic response in some patients.

"Our findings are limited by the shortened follow up time, which in most cases was less than one year. Despite that, our data are quite encouraging for this class of drugs, particularly because those who were treated for the longest and achieved the largest cholesterol reductions were the very patients who benefitted the most," said Ridker.
-end-
The trial sponsor, Pfizer, which manufactured bococizumab, provided a research grant to BWH to conduct the trial.

Brigham and Women's Hospital

Related Placebo Articles:

The placebo effect can mend a broken heart too, CU Boulder study shows
Feeling heartbroken from a recent breakup? Just believing you're doing something to help yourself get over your ex can influence brain regions associated with emotional regulation and lessen the perception of pain.
Successful insomnia treatment may require nothing more than a placebo
A new study published in Brain indicates that successful treatment for insomnia may not actually require complicated neurofeedback (direct training of brain functions).
Placebo and valium are equally effective for acute lower back pain in the ER
Emergency patients treated with naproxen and placebo had outcomes as good as or better than patients treated with naproxen and diazepam (trade name Valium) for acute lower back pain, according to the results of a double-blind, randomized clinical trial published last week in Annals of Emergency Medicine ('Diazepam Is No Better Than Placebo When Added to Naproxen for Acute Low Back Pain').
Evaluation of recombinant antithrombin vs. placebo in preterm preeclampsia
Researchers with the PRESERVE-1 Study Group University of Texas Health Science Center at Houston -- McGovern Medical School, Houston, Texas, and Yale School of Medicine, New Haven, Conn., present findings of a study titled Randomized double-blind placebo controlled evaluation of the safety and efficacy of recombinant Antithrombin versus placebo in preterm preeclampsia.
Exploiting the placebo effect can improve recovery of heart surgery patients
Exploiting the placebo effect significantly improved the recovery of patients undergoing heart surgery according to new research published in the open access journal BMC Medicine.
Placebo sweet spot for pain relief found in brain
Scientists have identified for the first time the region in the brain responsible for the placebo effect in pain relief.
Placebo reduces back pain -- even when patients know they're taking placebo
For patients with chronic back pain, 'open' treatment with placebo -- informing patients that they are taking an inactive pill, and why it might be helpful -- leads to reductions in pain and disability, reports a study in PAIN®, the official publication of the International Association for the Study of Pain.
Study finds knowingly taking placebo pills eases pain
This is the first study to demonstrate beneficial placebo effect for lower back pain sufferers who knew they were taking 'fake pills.' Patients who knowingly took placebos reported 30 percent less pain and 29 percent reduction in disability compared to control group.
Clinical trial tests spinal manipulation therapy for migraines
Manual-therapy randomized controlled trials (RCTs) are difficult to perform because it's challenging to conceal a placebo when patients are able to physically feel a treatment that's being delivered.
Anti-interleukin-1 alpha antibody MABp1 improves outcomes significantly over placebo
A novel anti-interleukin 1-alpha antibody has shown a significant impact on symptoms, and a high level of safety and tolerability in patients with advanced colorectal cancer, according to phase III data (1) presented at the European Society for Medical Oncology's 18th World Congress of Gastrointestinal Cancer in Barcelona, Spain.

Related Placebo Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Digital Manipulation
Technology has reshaped our lives in amazing ways. But at what cost? This hour, TED speakers reveal how what we see, read, believe — even how we vote — can be manipulated by the technology we use. Guests include journalist Carole Cadwalladr, consumer advocate Finn Myrstad, writer and marketing professor Scott Galloway, behavioral designer Nir Eyal, and computer graphics researcher Doug Roble.
Now Playing: Science for the People

#530 Why Aren't We Dead Yet?
We only notice our immune systems when they aren't working properly, or when they're under attack. How does our immune system understand what bits of us are us, and what bits are invading germs and viruses? How different are human immune systems from the immune systems of other creatures? And is the immune system so often the target of sketchy medical advice? Those questions and more, this week in our conversation with author Idan Ben-Barak about his book "Why Aren't We Dead Yet?: The Survivor’s Guide to the Immune System".